Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Columbia University
With
Grifols Therapeutics LLC
An increased risk of infection despite intensive antimicrobial prophylaxis is a well-recognized complication of lung transplantation. Recent evidence suggests that immunosuppressive therapy after solid organ transplantation may lead to humoral immunodeficiency due to hypogammaglobulinemia (HGG). In lung transplant recipients with HGG, IVIG therapy offers the potential to significantly decrease the incidence and severity of infections, thereby reducing morbidity and potentially mortality.
Comparison: The investigators are conducting a randomized clinical trial of IVIG versus placebo for lung transplant patients with severe HGG to see if IVIG decreases the number of bacterial infections in these patients.
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Lung transplant recipients \> 3 months after transplant surgery